StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Innate Pharma S.A. (IPHA)

Mon, 21 Sep 2026 07:33:58 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $7.00 price target on Innate Pharma S.A. (NASDAQ: IPHA).

The analyst commented: "On September 16, Innate Pharma announced that its strategic partnership with Swedish Orphan Biovitrum (SOBI; Buy; Kapoor) to license lacutamab in cutaneous T-cell lymphoma (CTCL) had closed and that it had received the $75M upfront payment (approximately equivalent to €65M). Innate remains eligible for up to $40M in near-term milestones connected to Sézary syndrome (SS) and up to $465M tied to Sobi’s option for full development rights and to future regulatory and commercial milestones, as well as tiered double-digit

Form 6-K Innate Pharma SA For: Sep 17

Thu, 17 Sep 2026 06:34:00 -0400

si-local-file:///var/storage/secattach/20260917/27072425.html

Form 6-K Innate Pharma SA For: Jun 30

Thu, 17 Sep 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260917/27072414.html

Form 6-K Innate Pharma SA For: Sep 16

Thu, 17 Sep 2026 06:22:00 -0400

si-local-file:///var/storage/secattach/20260917/27072375.html

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Thu, 17 Sep 2026 01:00:00 -0400

New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027

€30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio

IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed, with initial data to be presented at ENA 2026

PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026

Cash position of €21.4 million1 as of June 30, 2026

Anticipated cash horizon until the end of Q1 2028, taking into account the initial payment of $75 million

Innate Pharma Reports First Half 2026 Business Update and Financial Results

Thu, 17 Sep 2026 01:00:00 -0400

New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027

€30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio

IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed, with initial data to be presented at ENA 2026

PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026

Cash position of €21.4 million1 as of June 30, 2026

Anticipated cash horizon until the end of Q1 2028, taking into account the initial payment of $75 million

Innate Pharma and Sobi lacutamab partnership takes effect

Wed, 16 Sep 2026 16:00:22 -0400

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced that its strategic partnership with Sobi for the licensing of lacutamab in T-cell lymphoma is now effective, following the expiration of applicable antitrust waiting periods and the completion of other closing conditions.

The partnership, originally announced on August 10, 2026, triggers a $75 million upfront payment to Innate Pharma from Sobi. The closing also marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with the first patient enrollment expected in the first quarter of 2027.

Under the terms of the agreement, Innate Pharma will conduct the TELLOMAK-3 Phase 3 trial in cutaneous

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Wed, 16 Sep 2026 16:00:00 -0400

The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions

Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.
As announced on August

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

Wed, 16 Sep 2026 16:00:00 -0400

The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions

Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions.
As announced on August

Form 6-K Innate Pharma SA For: Sep 10

Thu, 10 Sep 2026 06:29:00 -0400
si-local-file:///var/storage/secattach/20260910/27044751.html

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Thu, 10 Sep 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026.
Participants in the call will be:

Jonathan Dickinson, Chief Executive Officer

Markus Jensen, Vice President, Chief Medical Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Event Details

Date and time: September 17, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT

Webcast link:

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

Thu, 10 Sep 2026 01:00:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026.
Participants in the call will be:

Jonathan Dickinson, Chief Executive Officer

Markus Jensen, Vice President, Chief Medical Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Event Details

Date and time: September 17, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT

Webcast link:

Form 6-K Innate Pharma SA For: Aug 19

Wed, 19 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260819/26949960.html

Form 6-K Innate Pharma SA For: Aug 19

Wed, 19 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260819/26949960.html

Form 6-K Innate Pharma SA For: Aug 19

Wed, 19 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260819/26949960.html

Form 6-K Innate Pharma SA For: Aug 14

Fri, 14 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260814/26924046.html

Form 6-K Innate Pharma SA For: Aug 14

Fri, 14 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260814/26924046.html

Form 6-K Innate Pharma SA For: Aug 14

Fri, 14 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260814/26924046.html

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link:

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/322508798
Participants may also join via telephone using the following registration link: